Synchrony Financial tops Q2 EPS estimates by 24.5% as record purchase volume, stronger loan growth and a higher 2026 EPS outlook offset rising expenses.
Synchrony Financial NYSE: SYF reported second-quarter 2026 net earnings of $885 million, or $2.59 per diluted share, as executives pointed to record purchase volume, renewed account growth and continued credit discipline during the company's earnings call.
While the top- and bottom-line numbers for Synchrony (SYF) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Synchrony (SYF) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.08 per share. This compares to earnings of $2.5 per share a year ago.
Will higher purchase volumes and a wider net interest margin help SYF top Q2 estimates? See the key factors shaping its July 21 earnings report.
Evaluate the expected performance of Synchrony (SYF) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Synchrony (SYF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synchrony Financial offers Series B fixed-rate reset preferreds, SYF.PR.B, with an 8.25% coupon, currently yielding ~8.04% at trading a slight premium to par. SYF.PR.B manages the interest rate risk versus fixed-rate preferreds, with coupon resetting in May 2029 to the five-year Treasury plus 4.044%. Synchrony's strong credit profile features a ~$15.25B common equity cushion and ~40x preferred dividend coverage, supporting preferred holders' security.
Synchrony Financial fixed-rate preferred offers a ~7.54% yield, trading at a discount due to higher market rates. SYF.PR.A enjoys strong dividend coverage (~40x quarterly, ~43x annual), strong capital ratios, and qualified dividend treatment for enhanced after-tax yield. Interest rate trajectory remains the primary risk; upside is capped at par, but discount mitigates call risk and allows for rate-reversal participation.
Watch more: Synchrony SMB Series With Beto Casellas of Synchrony and Dr. Priveer Sharma of Sharma Oral Surgery A patient sits in the chair needing an implant or a set of extractions and can't pay for it up front.
These days, that's been working pretty well. As one of the largest private-label credit card issuers in the United States, the company is making money, reducing loan losses, and handing billions back to shareholders.
Synchrony Financial (SYF) Presents at Morgan Stanley US Financials Conference 2026 Transcript